*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Toxicity of temozolamide in the treatment of glioblastoma; A case report

Author: SHAGHAYEGH KAMIAN, MARYAM AGHAJANIZADEH
Abstract: Glioblastoma is an astrocytic tumor with a poor prognosis. With the approval of temozolomide (TMZ) which is an alkylating agent used concurrent with radiation and continue as an adjuvant treatment, the survival is about 14 months. The uncommon side effect of this drug is myelosuppression, which can be observed in about 4% of patients. The grade 3 and 4 toxicity was observed rarely in the cases reported and due to cession of the treatment, the patients’ outcome were poor. We reported a case which had pancytopenia in the last days of chemoradiation and temozolamide was stopped and the patient was admitted for 2 weeks with severe supportive treatment. The patient was followed with blood tests and imaging of brain without any other treatment. He survived for 19 months. The report of treatment adverse effects especially chemotherapy, which is an essential part of treatment for brain tumors, is crucial for managing similar tumors in other cases.
Keyword: Brain Neoplasms, Temozolomide, Adverse Effects, Toxicity, Chemoradiotherapy, Survival
DOI: https://doi.org/10.31838/ijpr/2022.14.02.006
Download: Request For Article
 
Clients

Clients

Clients

Clients

Clients
ONLINE SUBMISSION
USER LOGIN
Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free